IGM Biosciences, Inc. - IGMS STOCK NEWS

IGM Biosciences has appointed Lisa L. Decker, Ph.D. as Chief Business Officer, a role aimed at expanding its business development efforts. Ms. Decker brings over 20 years of experience in the life sciences sector, previously leading business strategy at Atreca. The company's CEO highlighted her track record in forming partnerships and executing business strategies, crucial for advancing IGM’s innovative IgM technology platform. This move is expected to enhance IGM's focus on oncology, infectious diseases, and autoimmune diseases.

IGM Biosciences (Nasdaq: IGMS) will have CEO Fred Schwarzer participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021, at 2:00 p.m. ET. The event will be held virtually, with a live webcast available on the company's website. A replay will be accessible for 90 days following the presentation. IGM Biosciences specializes in developing engineered IgM antibodies to enhance therapeutic applications.

IGM Biosciences has announced an exclusive license agreement with Medivir AB to develop birinapant, a SMAC mimetic drug, in combination with its own IGM-8444 antibody for treating solid tumors. IGM will pay $1 million upfront and an additional $1.5 million upon inclusion of birinapant in Phase I studies. Medivir could earn up to $350 million in milestone payments and tiered royalties on net sales. The combination has shown promising results in preclinical studies. IGM plans to initiate clinical testing later this year.

IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. The presentation will focus on the company's development of engineered IgM antibodies. A live webcast will be accessible on the company's website, with an archived replay available for 90 days. IGM Biosciences has developed a proprietary IgM technology platform, aimed at overcoming challenges in the therapeutic application of IgM antibodies since its inception in 2010.

IGM Biosciences has successfully concluded an upsized public offering, selling a total of 1,221,224 shares of common stock at $90.00 each, alongside pre-funded warrants for 1,334,332 shares priced at $89.99. The offering raised approximately $230 million in gross proceeds. This capital will enhance IGM's capacity to develop engineered IgM antibodies utilizing its proprietary technology platform, aimed at improving therapeutic applications compared to IgG antibodies. Jefferies, Stifel, Guggenheim Securities, and RBC Capital Markets were the lead underwriters for this offering.

IGM Biosciences, Inc. (NASDAQ: IGMS) announced an upsized public offering of its common stock priced at $90.00 per share, along with pre-funded warrants at $89.99 each. The company aims to raise approximately $200 million in gross proceeds, which will support its growth. The offering includes a 30-day option for underwriters to purchase an additional $30 million in shares. The deal is expected to close around December 11, 2020, pending customary conditions. Jefferies, Stifel, Guggenheim Securities, and RBC Capital Markets are joint book-running managers for this offering.

IGM Biosciences, Inc. (NASDAQ: IGMS) announced plans to offer $150 million in shares of common stock and pre-funded warrants in an underwritten public offering. The offering includes a 30-day option for underwriters to purchase an additional $22.5 million. The securities will be offered under a Registration Statement filed with the SEC. The offering is subject to market conditions and there are no assurances on its completion. Jefferies, Stifel, Guggenheim Securities, and RBC Capital Markets are leading the offering.

IGM Biosciences (Nasdaq: IGMS) has reported preliminary results from its Phase 1 trial of IGM-2323, a bispecific IgM antibody targeting CD20 x CD3, at the ASH Annual Meeting. Out of 14 patients treated, 9 demonstrated tumor size reduction, with 2 achieving complete responses (CRs) after treatment at the 50/100 mg dose level. The study continues to evaluate escalating doses, aiming for an optimal dosing strategy. IGM-2323 appears well-tolerated, with no severe toxicities reported, suggesting a potentially safer alternative for B-cell malignancy treatment.

IGM Biosciences, a clinical-stage biotechnology firm, will host a conference call and live audio webcast on December 5, 2020, at 2:00 p.m. ET. This event follows the first clinical data presentation of IGM-2323 from their Phase 1 trial at the 62nd American Society of Hematology Annual Meeting. Interested parties can access the call by dialing (866) 649-1996 or (409) 217-8769, using conference ID 1141638. The call will also be available via a live webcast on their website, with a replay accessible for 90 days afterward.